1 / 56

GI Endocrinology: 101

GI Endocrinology: 101. Mark Feldman, MD. Case Presentation. A 56 year old woman has had diarrhea for 8 years, initially intermittent and now daily for 3 years. She stated “there’s not a bathroom in the state that I have not visited”. Diarrhea did not respond to OTC medications.

bregner
Download Presentation

GI Endocrinology: 101

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GI Endocrinology: 101 Mark Feldman, MD

  2. Case Presentation A 56 year old woman has had diarrhea for 8 years, initially intermittent and now daily for 3 years. She stated “there’s not a bathroom in the state that I have not visited”. Diarrhea did not respond to OTC medications.

  3. 56 y.o. with diarrhea, continued Past medical/surgical history: • morbid obesity (BMI 42 kg/m2) • status post TAH with BSO • Family history: • Mother: COPD, ulcers, kidney stones • Father: MI • Social history: negative • ROS: negative • Physical exam: morbid obesity. • CBC and chem 14: all normal except for ALT 54. • Stool microbiology studies negative. • Sigmoidoscopy were normal.

  4. Case: Imaging • Upper GI/SBFT : thickening of folds of stomach and proximal small intestine • Abdominal CT scan: thick gastric folds; slight prominence of the pancreatic head without a distinct mass; single gallstone; diffuse fatty infiltration of the liver. • EGD: prominent gastric folds; excessive gastric secretions (400 ml); no esophagitis or ulcers; 4 mm duodenal nodule biopsy: gastric metaplasia

  5. Biochemical tests • Fasting serum gastrin 1,200 pg/ml (normal, < 100) • Basal acid output after referral and on medication: • 57.4 mmol per hr (normal, < 5 mmol/hr) • Diagnosis: Zollinger-Ellison syndrome

  6. GI Endocrine System vs. Other Endocrine Tissues * Non-GI and GI tumors may coexist in the MEN-1 and MEN-2b syndromes

  7. D cells, G cells, and islets

  8. GI/Pancreatic Peptides That Function Mainly as Hormones • Secretin, the first hormone (1905) • Gastrin • Insulin • Glucagon, and related gene products (GLP-1, GLP-2, glicentin, oxyntomodulin) • Glucose-dependent insulinotropic peptide (GIP) • Motilin • Pancreatic polypeptide • Peptide tyrosine tyrosine (PYY)

  9. Gastrin-releasing peptide (GRP) nerves in human gastric mucosa

  10. GI Peptides That Act Principally as Neuropeptides • Calcitonin gene-related peptide (CGRP) • Dynorphin and related gene products • Enkephalin and related gene products • Galanin • Gastrin-releasing peptide (GRP) • Neuromedin U • Neuropeptide Y • Peptide histidine isoleucine (PHI) or peptide histidine methionine (PHM) • Pituitary adenylate cyclase–activating peptide (PACAP) • Substance P and other tachykinins (neurokinin A, neurokinin B) • Thyrotropin-releasing hormone (TRH) • VIP

  11. Paracrine inhibition of G cell release by somatostatin (STS) from adjacent D cells Gastric antral mucosa

  12. GI/Panreatic Peptides That May Function as Hormones, Neuropeptides, or Paracrine Agents • Somatostatin • Cholecystokinin (CCK) • Corticotropin-releasing factor (CRF) • Endothelin • Neurotensin

  13. GI/Pancreatic Peptides That Act as Growth Factors • Epidermal growth factor, EGF • Fibroblast growth factor, FGF • Insulin-like growth factors, IGF • Nerve growth factor, NGF • Platelet-derived growth factor, PDGF • Transforming growth factor-beta, TGFβ • Vascular endothelial growth factor, VEGF

  14. Peptides That Act asInflammatory Mediators • Interferons • Interleukins, e.g., IL-1, IL-6, IL-12 • Lymphokines • Monokines • TNFα

  15. Gastrointestinal peptides that regulate satiety and food intake Reduce meal sizeIncrease meal size CCK ghrelin GLP-1 PYY(3-36) gastrin releasing peptide amylin apolipoprotein A-IV somatostatin

  16. GI peptides that regulate postprandial blood glucose (incretins) • Glucagon-like peptide-1 (GLP-1) • Glucose-dependent insulinotropic peptide (GIP) • Gastrin releasing peptide • Cholecystokinin (potentiates amino acid-stimulated insulin release) • Gastrin (in presence of amino acids) • Vasoactive intestinal peptide (potentiates glucose-stimulated insulin release) • Pituitary adenylate cyclase activating peptide (potentiates glucose-stimulated insulin release) • Motilin

  17. GI GASTRINOMA SOMATOSTATINOMA CARCINOID OTHERS (RARE) PANCREATIC GASTRINOMA SOMATOSTATINOMA VIPOMA GLUCAGONOMA INSULINOMA PPOMA NONFUNCTIONAL GI Pancreatic Neoplasms

  18. Zollinger-Ellison Syndrome • “Islet cell” tumor of the pancreas [or of the duodenum]  • Hypergastrinemia  • Gastric acid hypersecretion  • Consequences of acid hypersecretion : • PUD, GERD [ with or without complications] • Diarrhea, malabsorption

  19. Epidemiology of Z-E syndrome • Any age group ( mean age  50 years) • Male : Female  3:2 • Annual incidence  0.5 - 1.0 per million • MEN-1 in approximately 25% of cases

  20. Classification of Z-E syndrome • Sporadic 75-80% • MEN-1(autosomal dominant) 20-25% • Ectopic gastrin- producing tumors < 1% • ovary • lung • cardiac (ventricular septum) • Non-gastrinoma islet tumor < 1%

  21. The Gastrinoma Triangle

  22. Pancreatic gastrinoma: gross pathology

  23. Pancreatic gastrinoma: histopathology

  24. Duodenal gastrinoma: low-power histopathology

  25. Duodenal gastrinoma: immunostaining for gastrin

  26. Histamine-producing (enterochromaffin-like) cell Parietal cell

  27. Gastrin stimulates parietal cells via neighboring ECL cells Serum Gastrin ECL CCKBR  hyperplasia Histamine H2R (PC) cAMP±Ca Gastric Acid Secretion  hyperplasia CCKBR (PC) Ca

  28. Enterochromaffin-like (ECL) cell hyperplasia

  29. Big folds

  30. Symptoms in patients with the Zollinger-Ellison syndrome • Pain and diarrhea 50-60% • Pain without diarrhea 25% • Diarrhea without pain 20% • Heartburn ± dysphagia 30% • MEN-1 features 20-25%

  31. Locations of peptic ulcers in ZE syndrome • Duodenal bulb • Post-bulbar duodenum • Jejunum • Esophagus • Stomach • Marginal (stomal)

  32. Clinical features suspicious for Zollinger-Ellison syndrome (ZES) • History of PUD and nephrolithiasis • Family history of PUD, kidney stones • PUD in the absence of Helicobacter pylori or NSAID usage • PUD in association with chronic diarrhea • Post-bulbar duodenal ulcer • Multiple duodenal and/or jejunal ulcers • PUD refractory to standard medical therapy

  33. Diagnosis of ZE Syndrome • Begins with clinical suspicion (pretest probability) • Fasting serum gastrin measurement • high sensitivity (> 95%) • poor specificity, even at high levels • modest positive predictive value • excellent negative predictive value

  34. Other causes of elevated fasting serum gastrin • Achlorhydria / hypochlorhydria, usu. due to chronic gastritis • Medications: antacids, PPIs, H2 blockers • Postoperative: vagotomy, retained antrum syndrome • Renal failure • Gastric outlet obstruction • Diabetes mellitus • Hypertriglyceridemia

  35. Diagnosis of ZE Syndrome • Fasting serum gastrin measurement • high sensitivity (> 95%) • low specificity and modest positive predictive value can be enhanced with provocative testing with secretin (2 IU/kg or 0.4 ug/kg i.v.) or calcium infusion (4 mg/kg calcium gluconate per hour for 3 hours), where likelihood ratios increase 10-15 fold with a + test result and decrease 10-fold with a - test result

  36. Management of ZE syndrome: • Acid control takes precedence over tumor search • Tumor search is designed to find tumor and to stage its/their extent • Tumor search and possible resection for cure is only prudent for patients who are surgical candidates

  37. Clinical symptoms and laboratory findings in patients with glucagonoma Clinical SymptomsFrequency (%) • Dermatitis 64-90 • Diabetes/glucose intolerance 38-90 • Weight loss 56-96 • Glossitis/stomatitis/cheilitis 29-40 • Diarrhea 14-15 • Abdominal pain 12 • Thromboembolic disease 12-35 • Venous thrombosis 24 • Pulmonary emboli 11 • Psychiatric disturbance uncommon Laboratory Abnormality • Anemia 33-85 • Hypoaminoacidemia 26-100 • Hypocholesterolemia 80 • Renal glycosuria unknown

  38. Glucagonoma syndrome.Necrolytic migratory erythema.

  39. Glucagonoma syndrome.Necrolytic migratory erythema.

  40. Clinical symptoms and laboratory findings in patients with the VIPoma syndrome (WDHA) Symptoms/SignsFrequency (%) Watery (secretory) diarrhea 89-100 Dehydration 44-100 Weight loss 36-100 Abdominal cramps, colic 10-63 Flushing 14-33 Laboratory Findings Hypokalemia 67-100 Hypochlorhydria 34-72 Hypercalcemia 41-50 Hyperglycemia 18-100

  41. Clinical and laboratory findings in patients with somatostatinomas Clinical Finding(s)SomatostatinomaSomatostatin syndr. PancreaticIntestinalOverall • Diabetes mellitus 95 21 95 • Gallbladder disease 94 43 68 • Diarrhea 66-97 11-36 37 • Weight loss 32-90 20-44 68 Laboratory Finding(s) • Steatorrhea 83 12 47 • Hypochlorhydria 86 17 26

  42. PANCREATIC IMAGING IN PANCREATIC ENDOCRINE TUMORS (PETS) * * GI IMAGING IS BY ENDOSCOPY IN MOST CASES

  43. IMAGING IN PANCREATIC ENDOCRINE TUMORS (PETS)

  44. MEN-1: MEN 2a: MEN 2b: Parathyroid tumor(s) Pancreatic tumor gastrin, insulin, VIP Pituitary tumor prolactin, ACTH Medullary thyroid Ca or hyperplasia Pheochromocytoma Parathyroid disease 2b , without parathyroid 2b, with gangioneuromatosis, Marfanoid habitus MEN syndromes

  45. Genetics of MEN-1 • Germ cell mutation at 11q13 in 90% of MEN-1, with loss of heterozygosity implicated in endocrine tumorigenesis • Chromosome 11q13 product is menin • Function of menin ? • Mutations in 11q13 also occur in several cases of “sporadic” islet cell tumors such as gastrinomas

  46. PETs in multiple endocrine neoplasia type I (MEN 1) syndrome

  47. Insulinomas in MEN-I

  48. Somatostatin-receptor scan in patient with MEN-1 and previous partial parathyroidectomy prolactinoma

  49. PET scan in same patient

  50. Prolactinoma removed by trans-sphenoidal resection in a young woman with amenorrhea

More Related